225 related articles for article (PubMed ID: 20532500)
1. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
Krug LM; Dao T; Brown AB; Maslak P; Travis W; Bekele S; Korontsvit T; Zakhaleva V; Wolchok J; Yuan J; Li H; Tyson L; Scheinberg DA
Cancer Immunol Immunother; 2010 Oct; 59(10):1467-79. PubMed ID: 20532500
[TBL] [Abstract][Full Text] [Related]
2. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
3. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
5. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
[TBL] [Abstract][Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
7. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA
Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
[TBL] [Abstract][Full Text] [Related]
9. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Kuball J; de Boer K; Wagner E; Wattad M; Antunes E; Weeratna RD; Vicari AP; Lotz C; van Dorp S; Hol S; Greenberg PD; Heit W; Davis HL; Theobald M
Cancer Immunol Immunother; 2011 Feb; 60(2):161-71. PubMed ID: 20963411
[TBL] [Abstract][Full Text] [Related]
10. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
13. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
14. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S
Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment.
Tan Z; Zhou J; Cheung AK; Yu Z; Cheung KW; Liang J; Wang H; Lee BK; Man K; Liu L; Yuen KY; Chen Z
Cancer Res; 2014 Nov; 74(21):6010-21. PubMed ID: 25125656
[TBL] [Abstract][Full Text] [Related]
16. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE
Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235
[TBL] [Abstract][Full Text] [Related]
20. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
